Celecoxib: a novel treatment for lung cancer

REFERENCES

• Surveillance Research — ACS. Lung and bronchus. In: Cancer Facts & Figures 2004. American Cancer Society, GA, USA, No. 5008–04 (2004).
   Google Scholar
• Chesnutt MS, Prendergast TJ. Lung: pulmonary neoplasms. In: Current Medical Diagnosis and Treatment, 431r1 Edition. Tierney LM Jr, McPhee SJ, Papadakis MA (Eds), Lang Medical Books/McGraw—Hill, NY, USA, 259–269 (2004).
   Google Scholar
• Hollen PJ, Gralla RJ, Kris MG et al. Normative data and trends in quality of life from the lung cancer symptom scale (LCSS). Support. Care Cancer7, 140–148 (1999).
   PubMed Web of Science ®Google Scholar
• Massarelli E, Andre F, Liu DD et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small cell lung cancer. Lung Cancer 39,55–61 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy regimens. Clin. Oiled 18, 2095–2103 (2003).
   Google Scholar
• Fosella FV, DeVore R, Kerr RN et al Randomized Phase III trial of vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. j Clin. Oncol 18, 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Steele VE, Sigman CC. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. In: COX-2 Blockade in Cancer Prevention and Therapy Harris RE (Ed.), Humana Press, NJ, USA, 279–300 (2003). Comprehensive review focusing on the strategies of chemopreventive and chemotherapeutic potential of nonsteroidal anti-inflammatory agents (NSAIAs), with special emphasis on cyclooxygenase (COX)-2 inhibitors, in several cancers including lung cancer.
   Google Scholar
• Mitchell JA, Akarasereenont P, Thiemermann C et al Selectivity of non-steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl Acad. Sci. USA. 90,11693–11697 (1994).
   Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol.) 231, 232–235 (1971).
   PubMedGoogle Scholar
• Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 13, 241–250 (1994).
   PubMed Web of Science ®Google Scholar
• DuBois RN, Awad J, Morrow J et al. Regulation of eicosanoids production and mitogenesis by transforming growth factor-13 and phorbol ester. j Clin. Investig: 93, 493–498 (1994).
   Google Scholar
• O'Neill GP, Ford-Hutchison AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330,156–160 (1993).
   PubMed Web of Science ®Google Scholar
• Needleman P, Isakson PC. The discovery and function of COX-2. I Rheumatol 24\(Suppl. 49), 6–8 (1997).
   Google Scholar
• Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes 1 and 2. Ann. NY Acad. Sci. 14,136-142 (1994).
   Google Scholar
• Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases 1 and 2: the mechanisms by which extracellular stimuli activate phospholipases are unresolved. Adv. Immunol 62,167–215 (1996).
   Google Scholar
• Subbaramaiah K, Zakin D, Dannenberg A. Inhibition of cyclooxygenase; a novel approach to cancer prevention. Exp. Biol. Med. 216,201–210 (1997).
   Google Scholar
• Graul A, Martel AM, Castanar J. Celecoxib. Drugs Futum22, 711–714 (1999).
   Google Scholar
• Weitzman SA, Gordon LI. Inflammation and cancer, role of phagocyte-generated oxidants in carcinogenesis. B/ooc/76,655–663 (1990).
   Google Scholar
• Hida T, Yatabe Y, Achiwa H et al Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58,3761–3764 (1998).
   PubMed Web of Science ®Google Scholar
• Wolff H, Saukkonen K, Anttila S et al Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997–5001 (1998).
   PubMed Web of Science ®Google Scholar
• McLemore TL, Hubbard WE, Litterst CL et al Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 48,3140–3147 (1988).
   PubMed Web of Science ®Google Scholar
• Hubbard WC, Alley MC, McLemore TL et al Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumors. Cancer Res. 48,4770–4775 (1988).
   PubMed Web of Science ®Google Scholar
• El-Bayoumy K, Iatropoulos M, Amin S et al Increased expression of cyclooxygenase-2 in rat lung tumor induced by the tobacco-specific nitrosamine 4-(methylnitrosamino) 4 (3 pyridy0-1-butanone: the impact of a high-fat diet. Cancer Res. 59,1400–1403 (1999).
   PubMed Web of Science ®Google Scholar
• Achiwa H, Yatabe Y, Hida Y et al Prognostic significance of elevated cyclooxygenase-2 expression in primary resected lung adenocarcinoma. Clin. Cancer Res. 5,1001-1005 (1999).
   Google Scholar
• Khuri FR, Wu H, Lee JJ et al COX-2 overexpression is a marker of poor prognosis in Stage I non-small cell lung cancer. Clin. Cancer Res. 7,861-867 (2001).
   Google Scholar
• Hosomi Y, Yokose T, Hirose Y et al. Increased cyclooxygenase-2 expression occurs frequently in precursor lesions of human adenocarcinomas of lung. Lung Cancer 30,73–81 (2000).
   PubMed Web of Science ®Google Scholar
• Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig Drugs 8,1623–1638 (1999).
   Google Scholar
• Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology5, 138–146 (1994).
   PubMed Web of Science ®Google Scholar
• Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep. 9, 693–695 (2002).
   PubMed Web of Science ®Google Scholar
• Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Catrinogenesis 18,1001–1006 (1997).
   PubMed Web of Science ®Google Scholar
• Pious N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetyl salicylic acid and NS-398. Cancer Res. 58,5354–5360 (1998).
   PubMed Web of Science ®Google Scholar
• Yao R, Pious N, Castonguay A. Inhibition of COX-2 and induction of apoptosis. Two determinants of non-steroidal anti-inflammatory drugs chemopreventive efficacy in mouse lung tumorigenesis. Exp. Lung Res. 26,731-742 (2000).
   Google Scholar
• Stolina M, Sharma S, Lin Y et al Specific inhibition of cyclooxygenase-2 restore antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. I Immunol 164,361–370 (2000).
   PubMed Web of Science ®Google Scholar
• Castonguay A, Pious N, Duperron C et al Inhibition of lung tumorigenesis by NSAIDs. A working hypothesis. Bp. Lung Res. 24,605–615 (1989).
   Google Scholar
• Hida T, Kozaki KI, Muramatsu H. Cyclooxygenase-2 inhibitor induced apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6, 2006–2011 (2000).
   Google Scholar
• Dipema CA, Bart RD, Sievers EM et al. Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. I Thorac. Camliovasc. Surg. 126,1129-1133 (2003).
   Google Scholar
• Liu W, Chen Y, Wang W et al Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am. I Clin. Oncol 26(Suppl.), S103—S109 (2003).
   Google Scholar
• Pyo H, Choy H, Amorino GP et al A selective cyclooxygenase-2 inhibitor NS-398 enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 7,2998-3005(2001).
   Google Scholar
• Hida T, Kozaki KI, Ito H. Significant growth inhibition of human lung cancer cells in rdtm and in Ova by the combined use of a selective cyclooxygenase-2 inhibitor JTE-522 and conventional anticancer agents. Clin. Cancer Res 8,2443–2447 (2002).
   Google Scholar
• •Demonstrated that the selective COX-2 inhibitorTFE-522 exerts an antitumor effect in non-small cell lung cancer (NSCLC), both in iinv and in iiver4 without adverse effects when used alone or in combination with cytotoxic chemotherapy.
   Google Scholar
• Milas L, Kishi K, Hunter N et al Enhancement of tumor response to y-radiation by an inhibitor of cyclooxygenase-2 enzyme. I Natl Cancer Inst. 91,1501–1504 (1999).
   PubMed Web of Science ®Google Scholar
• Kishi K, Peterson S, Peterson C et al Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60,1326–1331 (2000).
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60, 1306–1311 (2000).
   PubMed Web of Science ®Google Scholar
• ••Emphasizes the process of angiogenesis intumorigenesis and argues the reasons for a novel application of the antiangiogenic COX-2 inhibitors in the treatment of human cancer.
   Google Scholar
• Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Rad. Oncol 11, 290–299 (2001).
   Google Scholar
• Keller SM, Adak S, Wagner H et al A randomized trial of postoperative adjuvant therapy in patients with complete resected Stage II or IIIA non-small cell lung cancer. N. Engl Med 343,1217–1222 (2000).
   PubMed Web of Science ®Google Scholar
• Altorki NK, Kereszles RS, Port JL et al Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early stage non-small cell lung cancer. Clin. Oncol 21,2645-2650 (2003). •• First Phase II clinical study demonstrating that celecoxib, a COX-2 inhibitor, enhances the clinical response of cytotoxic chemotherapy in patients with early stage NSCLC.
   Google Scholar
• Carbone D, Choy H, Ciski I et al Serum/plasma VEGF level changes with cyclooxygenase-2 (COX-2) inhibition in combined modality therapy in Stage III non-small cell lung cancer (NSCLC): preliminary results of a Phase II trial. Proc. Am Soc. Clin. Oncol 21,1270 (2002).
   Google Scholar
• Gridelli C, Malone P, Airoma G et al Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Cum Med. Chem. 9, 1851–1858 (2002).
   Google Scholar
• •Brief summary that explains the role of COX-2 inhibitors and their mechanisms in treatment of NSCLC.
   Google Scholar
• Komaki R, Liao Z, Milas L. Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin. Oncol 31 (Suppl. 1), 47–53 (2004).
   Google Scholar
• Hubbard WC, Alley MC, Gray GN et al. Evidence for prostanoid biosynthesis as a biochemical feature of certain subclass of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res. 49, 8266–8268 (1989).
   Web of Science ®Google Scholar
• Rose DP, Hatala AM, Connolly JM et al Effect of diets containing different levels of linoleic acid on human breast cancer growth and lung metastasis in mice. Cancer Res. 53,4686–4690 (1993).
   PubMed Web of Science ®Google Scholar
• Rose DP, Connolly JM. Stimulation of growth of human breast cancer lines in culture by linoleic acid. Biochem. Biophys. Res. Commun. 164, 277–283 (1989).
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Kawano S et al Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Ce1193, 705–716 (1998).
   Google Scholar
• Masferrer JL, Koki A, Seibert K. COX-2 inhibitors: a new class of antiangiogenic agents. Ann. NY Acad. Sc]. 889, 84–86 (1999).
   Google Scholar
• Balch CM, Dougherty PA, Cloud GA et al Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95, 75–77 (1984).
   Web of Science ®Google Scholar
• McDougall CJ, Ngoi SS, Goldman IS et al Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res. 50, 8023–8027 (1990).
   PubMed Web of Science ®Google Scholar
• Shou M, Korzekwa KR, Krause KW et al Specificity of cDNA-expressed human and rodent cytochrome P450 in the oxidative metabolism of the potent carcinogen 7,12-dimethyl benz(a)anthracene. Mal Carcinog. 17, 241–249 (1996).
   PubMed Web of Science ®Google Scholar
• Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Ce1183, 493–501 (1995).
   Google Scholar
• Grosch S, Tegeder I, Niederberger E et al COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15,2742–2744 (2001).
   PubMed Web of Science ®Google Scholar
• Chan TA, Morin PJ, Vogelstein B et al. Mechanisms underlying non-steroidal anti-inflammatory drugs-mediated apoptosis. Proc. Nail Acad. Sc]. USA 95,681–686 (1998).
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, Kawano S, DuBois RN. COX-2 expression in human colon cancer cells increases metastatic potential. Proc. Nail Acad. Sc]. USA 94,3336–33340 (1997).
   Google Scholar
• Sheng H, Shao J, Morrow JD. Modulation of apoptosis and bc1-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58, 362–366 (1998).
   Google Scholar
• Liu X, Yao S, Kirschenbaum A et al NS-398, a selective cyclooxygenase-2 inhibitor induces apoptosis and downregulates bc1-2 expression in LNCaP cells. Cancer Res 58(19), 4245–4249 (1998).
   Google Scholar
• He T-C, Chan TA, Vogelstein B et al PPAR-y is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell 99,335–345 (1999).
   PubMed Web of Science ®Google Scholar
• Lin MT, Lee RC, Yang PC et al Cyclooxygenase-2 inducing mcl-1 dependent survival mechanism in human lung adenocarcinoma CLIO cells. j Biol. Chem. 276, 48997–49902 (2001).
   Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Form DM, Auerbach R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 172, 214–218 (1983).
   Google Scholar
• Jones MK, Wang H, Peskar PM et al Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs; insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med. 5, 1418–1423 (1999).
   PubMed Web of Science ®Google Scholar
• Hanif R, Pittas A, Feng Y et al Effects of NSAIDs on proliferation and induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol 52, 237–245 (1996).
   PubMed Web of Science ®Google Scholar
• Piazza GA, Rahm AL, Krutsch MI et al Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55,3110–3116 (1995).
   PubMed Web of Science ®Google Scholar
• Duggan DE, Hare LE, Ditzler GA et al The disposition of sulindac. Clin. Pharmacol Ther. 21, 236–335 (1977).
   Web of Science ®Google Scholar
• Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of NSAIDs. I Exp. Med. 190, 445–450 (1999).
   PubMed Web of Science ®Google Scholar
• Isakson E Zweifel B, Masferrer J et al Specific COX-2 inhibitors from bench to bedside. In: Selective COX-2 Inhibitors.: Pharmacologx Clinical Effects and Therapeutic Potential Vane J, Botting J (Eds), William Harvey Press, London, UK, 127–133 (1997).
   Google Scholar
• Brooks PM, Day RD. COX-2 inhibitors. Med Aust. 173,433–436 (2000).
   PubMed Web of Science ®Google Scholar
• Penning TD, Talley JJ, Bertenshaw SR et al Synthesis and biological evaluation of the 1,5-diaryl pyrazole class of cyclooxygenase-2 inhibitors. j Med. Chem. 40,1347-1365 (1997).
   Google Scholar
• Pamham MJ. Inflammation, mechanisms and therapeutics. Drugs New Pempect. 9, 631–639 (1996).
   Google Scholar
• Lanza FL, Rack ME A pilot endoscopy study of the gastro duodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastrventerology112, A194 (1997).
   Web of Science ®Google Scholar
• Simon LS, Lanza FL, Lipsky PE et al Preliminary study of the safety and efficacy of SC-58635, a novel COX-2 selective inhibitor; efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 41, 1591–1602 (1998).
   PubMed Web of Science ®Google Scholar
• Mengle-Gaw L, Hubbard RC, Karim A et al A study of the platelet effect of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheum. 40(Suppl.), S93 (1997).
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL et al Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study; a randomized controlled trial. JA/V/A 284, 1247–1255 (2000).
   Google Scholar
• Simon LS, Weaver AL, Graham AY et al Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JA/V/4 282, 1921–1928 (1999) .
   Google Scholar
• Emery P, Zeidler H, Kvien TK et al Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet354, 2106–2111 (1999).
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK et al The effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis. N Engl. Med. 432, 1946–1952 (2000).
   Google Scholar